Matthew L. Kaplan - 05 Nov 2025 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Role: Director
Signature: /s/ Matthew Kaplan
Issuer symbol: NVCT
Transactions as of: 05 Nov 2025
Net transactions value: +$64,240
Form type: 4
Filing time: 06 Nov 2025, 08:00:15 UTC
Previous filing: 12 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kaplan Matthew L.	Director	C/O NUVECTIS PHARMA, INC.,, 1 BRIDGE PLAZA, SUITE 275, FORT LEE	/s/ Matthew Kaplan	06 Nov 2025	0001895952

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCT	Common Stock	Purchase	$64,240	+11,000	+9.7%	$5.84	124,760	05 Nov 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.81 to $5.88. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

Content

Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.81 to $5.88. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.